Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Enanta Pharmaceuticals (ENTA) Shares Outstanding (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Shares Outstanding readings, the most recent being $29.0 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 36.03% to $29.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.0 million, a 36.03% increase, with the full-year FY2025 number at $21.4 million, changed 0.0% from a year prior.
  • Shares Outstanding hit $29.0 million in Q4 2025 for Enanta Pharmaceuticals, up from $21.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $29.0 million in Q4 2025 to a low of $20.2 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $21.1 million (2023), compared with a mean of $21.3 million.
  • The widest YoY moves for Shares Outstanding: up 36.03% in 2025, down 0.0% in 2025.
  • Enanta Pharmaceuticals' Shares Outstanding stood at $20.5 million in 2021, then grew by 1.84% to $20.9 million in 2022, then rose by 1.3% to $21.2 million in 2023, then grew by 0.84% to $21.3 million in 2024, then skyrocketed by 36.03% to $29.0 million in 2025.
  • The last three reported values for Shares Outstanding were $29.0 million (Q4 2025), $21.4 million (Q3 2025), and $21.4 million (Q2 2025) per Business Quant data.